Use of N-acetylcysteine in Obsessive-Compulsive and Related Disorders

References

• Berk M, Malhi GS, Gray LJ, Dean OM. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci 2013; 34(3): 167–7. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 2005; 58(5): 424–8. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Odlaug BL, Grant JE. N-acetyl cysteine in the treatment of grooming disorders. J Clin Psychopharmacol 2007; 27(2): 227–9. [CrossRef]
   Web of Science ®Google Scholar
• Coric V, Kelmendi B, Pittenger C, Wasylink S, Bloch MH, Green J. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with trichotillomania. J Clin Psychiatry 2007; 68(1)170–1. [CrossRef]
   Web of Science ®Google Scholar
• Sansone RA, Sansone LA. Getting a Knack for NAC: N-Acetyl-Cysteine. Innov Clin Neurosci 2011; 8(1): 10–4.
   Google Scholar
• Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia: A double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008; 64(5): 361–8. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008; 64(6): 468–5. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Hardan AY, Fung LK, Libove RA, Obukhanych TV, Nair S, Herzenberg LA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry 2012; 71(11): 956–1. [CrossRef]
   PubMed Web of Science ®Google Scholar
• LaRowe SD, Mardikian P, Malcolm R, Myrick H, Kalivas P, McFarland K, et al. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict 2006; 15(1): 105–10. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007; 62(6): 652–7. [CrossRef]
   PubMed Web of Science ®Google Scholar
• LaRowe SD, Myrick H, Hedden S, Mardikian P, Saladin M, McRae A, et al. Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatry 2007; 164(7): 1115–7.
   PubMed Web of Science ®Google Scholar
• Mardikian PN, LaRowe SD, Hedden S, Kalivas PW, Malcolm RJ. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(2): 389–94. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008; 33(9): 2187–99. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS, et al. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord 2011; 135(1–3): 389–94. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Magalhaes PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, et al. N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr 2011; 33(4): 374–8. [CrossRef]
   Web of Science ®Google Scholar
• Karila L, Gorelick D, Weinstein A, Noble F, Benyamina A, Coscas S, et al. New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol 2008; 11(3): 425–38. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Reichel CM, Moussawi K, Do PH, Kalivas PW, See RE. Chronic N-acetylcysteine during abstinence or extinction after cocaine self-administration produces enduring reductions in drug seeking. J Pharmacol Exp Ther 2011; 337(2): 487–93. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Schmaal L, Berk L, Hulstijn KP, Cousijn J, Wiers RW, van den Brink W. Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot study. Eur Addict Res 2011; 17(4): 211–6. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Derakhshan N. N-acetylcysteine for treatment of autism, a case report. J Res Med Sci 2012; 17(10): 985–7.
   Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: American Psychiatric Publishing, 2013.
   Google Scholar
• Hautmann G, Hercogova J, Lotti T. Trichotillomania. J Am Acad Dermatol 2002; 46(6): 807–21. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Chamberlain SR, Fineberg NA, Blackwell AD, Clark L, Robbins TW, Sahakian BJ. A neuropsychological comparison of obsessive-compulsive disorder and trichotillomania. Neuropsychologia 2007; 45(4): 654–62. [CrossRef]
   Web of Science ®Google Scholar
• Grant JE, Potenza MN. Compulsive aspects of impulse-control disorders. Psychiatr Clin North Am 2006; 29(2): 539–51. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Swedo SE, Leonard HL. Trichotillomania: an obsessive compulsive spectrum disorder? Psychiatr Clin North Am 1992; 15(4): 777–90.
   PubMed Web of Science ®Google Scholar
• Stein DJ, Simeon D, Cohen LJ, Hollander E. Trichotillomania and obsessive-compulsive disorder. J Clin Psychiatry 1995; (56): 28–34.
   Google Scholar
• Moran MM, McFarland K, Melendez RI, Kalivas PW, Seamans JK. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci 2005; 25(27): 6389–93. [CrossRef]
   Web of Science ®Google Scholar
• Bonanomi L, Gazzaniga A. Toxicological, pharmacokinetic and metabolic studies on acetylcysteine. Eur J Respir Dis 1980; 111(Suppl.): S45–S51.
   Google Scholar
• Vina J, Reginald H, Krebs HA. Maintenance of glutathione content in isolated hepatocytes. Biochem J 1978; 170(3): 627–30.
   PubMed Web of Science ®Google Scholar
• Sjodin K, Nilsson E, Hallberg A, Tunek A. Metabolism of N-acetyl-L-cysteine. Some structural requirements for the deacetylation and consequences for the oral bioavailability. Biochem Pharmacol 1989; 38(22): 3981–5. [CrossRef]
   Google Scholar
• Borgström L, Kagedal B. Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing to man. Biopharm Drug Dispos 1990; 11(2): 131–6. [CrossRef]
   Web of Science ®Google Scholar
• Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. Eur J Clin Pharmacol 1992; 43(6): 667–9. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Samuni Y, Goldstein S, Dean OM, Berk M. The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta 2013; 1830(8): 4117–29. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Neuwelt EA, Pagel MA, Hasler BP, Deloughery TG, Muldoon LL. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. Cancer Res 2001; 61(21): 7868–74.
   Web of Science ®Google Scholar
• Dean O, van den Buuse M, Copolov D, Berk M, Bush A. N-acetylcysteine inhibits depletion of brain glutathione levels in rats: implications for schizophrenia Neuropsychopharmacol 2004; 7(Suppl.2): S262.
   Google Scholar
• Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, et al. The antioxidants alphalipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem 2003; 84(5): 1173–83. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Bloch MH, Panza KE, Grant JE, Pittenger C, Leckman JF. N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. J Am Acad Child Adolesc Psychiatry 2013; 52(3): 231–40. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Egashira N, Shirakawa A, Abe M, Niki T, Mishima K, Iwasaki K, et al. N-acetyl-L-cysteine inhibits marble-burying behavior in mice. J Pharmacol Sci 2012; 119(1): 97–101. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Pendyala L, Creaven PJ. Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a phase I trial. Cancer Epidemiol Biomarkers Prev 1995; 4(3): 245–51.
   PubMed Web of Science ®Google Scholar
• Allegra L, Dal Sasso M, Bovio C, Massoni C, Fonti E, Braga PC. Human neutrophil oxidative bursts and their in vitro modulation by different N-acetylcysteine concentrations. Arzneimittelforschung 2002; 52(9): 669–76.
   Web of Science ®Google Scholar
• Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. N-Acetylcysteine-a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 2007; 7(4): 355–9. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Smith QR. Transport of glutamate and other amino acids at the blood-brain barrier. J Nutr 2000; 130(Suppl.4): 1016–22.
   Web of Science ®Google Scholar
• De Rosa SC, Zaretsky MD, Dubs JG, Roederer M, Anderson M, Green A, et al. N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest 2000; 30(10): 915–29. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Bloch MH. Trichotillomania across the life span. J Am Acad Child Adolesc Psychiatry 2009; 48(9): 879–83. [CrossRef]
   Web of Science ®Google Scholar
• Palmer LA, Doctor A, Chhabra P, Sheram ML, Laubach VE, Karlinsey MZ, et al. S-nitrosothiols signal hypoxia-mimetic vascular pathology. J Clin Invest 2007; 117(9): 2592–601. [CrossRef]
   Web of Science ®Google Scholar
• Devi PU, Pillai KK, Vohora D. Facilitation action of N-acetylcysteine on the anticonvulsant effect of sodium valproate in mice. Basic Clin Pharmacol Toxicol 2006; 98(5): 521–2. [CrossRef]
   Web of Science ®Google Scholar
• Bailey B, Blais R, Letarte A. Status epilepticus after a massive intravenous N-acetylcysteine overdose leading to intracranial hypertension and death. Ann Emerg Med 2004; 44(4): 401–6. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Berk M, Ng F, Dean O, Dodd S, Bush AI. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci 2008; 29(7): 346–51. [CrossRef]
   Web of Science ®Google Scholar
• Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008; 11(6): 851–76. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006; 3(1): 69–81. [CrossRef]
   Google Scholar
• Dodd S, Dean O, Copolov DL, Malhi GS, Berk M. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther 2008; 8(12): 1955–62. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Aitio ML. N-acetylcysteine-passe-partout or much ado about nothing? Br J Clin Pharmacol 2006; 61(1): 5–15. [CrossRef]
   Web of Science ®Google Scholar
• Baker DA, Xi ZX, Shen H, Swanson CJ, Kalivas PW. The origin and neuronal function of in vivo nonsynaptic glutamate. J Neurosci 2002; 22(20): 9134–41.
   PubMed Web of Science ®Google Scholar
• Wright RA, Arnold MB, Wheeler WJ, Ornstein PL, Schoepp DD. [3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain. J Pharmacol Exp Ther 2001; 298(2): 453–60.
   PubMed Web of Science ®Google Scholar
• Schoepp DD. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 2001; 299(1): 12–20.
   PubMed Web of Science ®Google Scholar
• Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology 2006; 184(2): 254–6. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Baker DA, McFarland K, Lake RW, Shen H, Toda S, Kalivas PW. N-acetyl cysteine-induced blockade of cocaine-induced reinstatement. Ann N Y Acad Sci 2003; 1003: 349–51. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Camfield DA, Sarris J, Berk M. Nutraceuticals in the treatment of obsessive compulsive disorder (OCD): a review of mechanistic and clinical evidence. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(4): 887–95. [CrossRef]
   Web of Science ®Google Scholar
• Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a doubleblind, placebo-controlled study. Arch Gen Psychiatry 2009; 66(7): 756–63. [CrossRef]
   PubMed Web of Science ®Google Scholar
• McFarland K, Lapish CC, Kalivas PW. Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. J Neurosci 2003; 23(8): 3531–7.
   PubMed Web of Science ®Google Scholar
• Kalivas PW, Volkow N, Seamans J. Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission. Neuron 2005; 45(5): 647–50. [CrossRef]
   Web of Science ®Google Scholar
• Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005; 162(8): 1403–13. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Murphy T, Miyamoto M, Sastre A, Schnaar LR, Coyle JT. Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron 1998; 2(6): 1547–58. [CrossRef]
   Google Scholar
• Han D, Sen CK, Roy S, Kobayashi MS, Tritschler HJ, Packer L. Protection against glutamate-induced cytoxicity in C6 glial cells by thiol antioxidants. Am Physiol Soc 1997; 273(5): 1771–8.
   Web of Science ®Google Scholar
• Noble A, MacDonald A. Drug-induced hepatotoxicity. N Engl J Med 1996; 28:334(13): 864.
   Google Scholar
• Oka A, Belliveau MJ, Rosenberg PA, Volpe JJ. Vulnerability of oligodendroglia to glutamate: pharmacology, mechanisms, and prevention. J Neurosci 1993; 13(4): 1441–53.
   PubMed Web of Science ®Google Scholar
• Cotgreave IA. N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv Pharmacol 1997; 38: 205–27.
   PubMedGoogle Scholar
• Dringen R, Hirrlinger J. Glutathione pathways in the brain. Biol Chem 2003; 384(4): 05–516. [CrossRef]
   Web of Science ®Google Scholar
• Mayer M, Noble M. N-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc Natl Acad Sci USA 1994; 91(16): 7496–500. [CrossRef]
   Web of Science ®Google Scholar
• Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 2011; 36(2): 78–86. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989; 6(6): 593–7. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Wang CC, Fang KM, Yang CS, Tzeng SF. Reactive oxygen species-induced cell death of rat primary astrocytes through mitochondria-mediated mechanism. Journal of Cellular Biochemistry 2009; 107(5): 933–43. [CrossRef]
   Web of Science ®Google Scholar
• Otte DM, Sommersberg B, Kudin A, Guerrero C, Albayram O, Filiou MD, et al. N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic mice. Neuropsychopharmacology 2011; 36(11): 2233–43. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Baker DA, McFarland K, Lake RW, Shen H, Tang XC, Toda S, et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci 2003; 6(7): 743–9. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Hastings TG. The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease. J Bioenerg Biomembr 2009; 41(6): 469–72. [CrossRef]
   Web of Science ®Google Scholar
• Hirrlinger J, Schulz JB, Dringen R. Glutathione release from cultured brain cells: multidrug resistance protein 1 mediates the release of GSH from rat astroglial cells. J Neurosci Res 2002; 69(3): 318–26. [CrossRef]
   Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: American Psychiatric Publishing, 1994.
   Google Scholar
• Murray CJ, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and morbidity from diseases, injuries, and risk factors in 1990 and projected to 2020, Cambridge: Published by Harvard University Press, 1996 p.1–43.
   Google Scholar
• Bobes J, González MP, Bascarán MT, Arango C, Sáiz PA, Bouso-o M. Quality of life and disability in patients with obsessive-compulsive disorder. Eur Psychiatry 2001; 16(4): 239–45. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Rasmussen SA, Eisen JL. The epidemiology and differential diagnosis of obsessive compulsive disorder. J Clin Psychiatry 1992; 53(Suppl.): S4–S10. [CrossRef]
   PubMedGoogle Scholar
• Sarris J, Camfield D, Berk M. Complementary medicine, self-help, and lifestyle interventions for obsessive compulsive disorder (OCD) and the OCD spectrum: a systematic review. J Affect Disord 2012; 138(3): 213–21. [CrossRef]
   Web of Science ®Google Scholar
• Dell'Osso B, Nestadt G, Allen A, Hollander E. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: a critical review. J Clin Psychiatry 2006; 67(4): 600–10. [CrossRef]
   Web of Science ®Google Scholar
• Denys D, Van Nieuwerburgh F, Deforce D, Westenberg HG. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry 2007; 68(5): 747–53. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int JNeuropsychopharmacol 2005; 8(1): 107–29. [CrossRef]
   Web of Science ®Google Scholar
• Jenike MA. Obsessive-compulsive disorder. N Engl J Med 2004; 350(3): 259–65. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Mataix-Cols D, Rauch SL, Baer L, Eisen JL, Shera DM, Goodman WK, et al. Symptom stability in adult obsessive-compulsive disorder: data from a naturalistic two-year follow-up study. Am J Psychiatry 2002; 159(2): 263–8. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, et al. International Treatment Refractory OCD Consortium. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002; 5(2): 181–91. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005; 30(9): 1735–40. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry 2006; 63(7): 769–76. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Arnold PD, Rosenberg DR, Mundo E, Tharmalingam S, Kennedy JL, Richter MA. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology 2004; 174(4): 530–8. [CrossRef]
   PubMed Web of Science ®Google Scholar
• McGrath MJ, Campbell KM, Parks CR, Burton FH. Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder. Brain Res 2000; 877(1): 23–30. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 2000; 39(9): 1096–103. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Rosenberg DR, Mirza Y, Russell A, Tang J, Smith JM, Banerjee SP, et al. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry 2004; 43(9): 1146–53. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Saxena S, Rauch SL. Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatr Clin North Am 2000; 23(3): 563–86. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L, et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol 2010; 30(1): 34–9. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Behl A, Swami G, Sircar SS, Bhatia MS, Banerjee BD. Relationship of possible stress-related biochemical markers to oxidative/antioxidative status in obsessive-compulsive disorder. Neuropsychobiology 2010; 61(4): 210–4. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Singh OP, Dasgupta A, Mandal N, Nath Das H. Correlation between lipid peroxidation-induced TBARS level and disease severity in obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(2): 363–6. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Ersan S, Bakir S, Erdal Ersan E, Dogan O. Examination of free radical metabolism and antioxidant defence system elements in patients with obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(6): 1039–42. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Konuk N, Tekin IO, Ozturk U, Atik L, Atasoy N, Bektas S, et al. Plasma levels of tumor necrosis factor-alpha and interleukin-6 in obsessive compulsive disorder. Mediators Inflamm 2006; 2007: 1–5. [CrossRef]
   Google Scholar
• Ozdemir E, Cetinkaya S, Ersan S, Kucukosman S, Ersan EE. Serum selenium and plasma malondialdehyde levels and antioxidant enzyme activities in patients with obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(1): 62–5. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Ichimaru Y, Egawa T, Sawa A. 5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Jpn J Pharmacol 1995; 68(1): 65–70. [CrossRef]
   PubMedGoogle Scholar
• Harasawa T, Ago Y, Itoh S, Baba A, Matsuda T. Role of serotonin type 1A receptors in fluvoxamine-induced inhibition of marble-burying behavior in mice. Behav Pharmacol 2006; 17(7): 637–40. [CrossRef]
   Web of Science ®Google Scholar
• Egashira N, Okuno R, Harada S, Matsushita M, Mishima K, Iwasaki K, et al. Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder. Eur J Pharmacol 2008; 586(1–3): 164–70. [CrossRef]
   PubMed Web of Science ®Google Scholar
• King RA, Zohar AH, Ratzoni G, Binder M, Kron S, Dycian A, et al. An epidemiological study of trichotillomania in Israeli adolescents. J Am Acad Child Adolesc Psychiatry 1995; 34(9): 1212–5. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Christenson GA, Pyle RL, Mitchell JE. Estimated lifetime prevalence of trichotillomania in college students. J Clin Psychiatry 1991; 52(10): 415–7.
   PubMed Web of Science ®Google Scholar
• Keuthen NJ, Fraim C, Deckersbach T, Dougherty DD, Baer L, et al. Longitudinal follow-up of naturalistic treatment outcome in patients with trichotillomania. J Clin Psychiatry 2001; 62(2): 101–7. [CrossRef]
   Web of Science ®Google Scholar
• Christenson GA, Mackenzie TB, Mitchell JE. Characteristics of 60 adult chronic hair pullers. Am J Psychiatry 1991; 148(3): 365–70. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Bloch MH, Landeros-Weisenberger A, Dombrowski P, Kelmendi B, Wegner R, Nudel J, et al. Systematic review: pharmacological and behavioral treatment for trichotillomania. Biol Psychiatry 2007; 62(8): 839–46. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Swedo SE, Lenane MC, Leonard HL. Long-term treatment of trichotillomania (hair pulling). N Engl J Med 1993; 329(2): 141–2. [CrossRef]
   Web of Science ®Google Scholar
• Van Ameringen M, Mancini C, Patterson B, Bennett M, Oakman J. A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. J Clin Psychiatry 2010; 71(10): 1336–43. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Stein DJ, Hollander E. Low-dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania. J Clin Psychiatry 1992; 53(4): 123–6.
   Web of Science ®Google Scholar
• De Sousa A. An open-label pilot study of naltrexone in childhood-onset trichotillomania. J Child Adolesc Psychopharmacol 2008; 18(1): 30–3. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Rodrigues-Barata AR, Tosti A, Rodríguez-Pichardo A, Camacho-Martínez F. N-acetylcysteine in the Treatment of Trichotillomania. Int J Trichology 2012; 4(3): 176–8. [CrossRef]
   Google Scholar
• Bohne A, Keuthen N, Wilhelm S. Pathologic hairpulling, skin picking, and nail biting. Ann Clin Psychiatry 2005; 17(4): 227–32. [CrossRef]
   Google Scholar
• Creath CJ, Steinmetz S, Roebuck R. A case report. Gingival swelling due to a fingernail-biting habit. J Am Dent Assoc 1995; 126(7): 1019–21. [CrossRef]
   Web of Science ®Google Scholar
• Ghanizadeh A, Shekoohi H. Prevalence of nail biting and its association with mental health in a community sample of children. BMC Res Notes 2011; 4: 116. [CrossRef]
   PubMedGoogle Scholar
• Ghanizadeh A, Derakhshan N, Berk M. N-acetylcysteine versus placebo for treating nail biting, a double blind randomized placebo controlled clinical trial. Antiinflamm Antiallergy Agents Med Chem 2013; 12(3): 223–8. [CrossRef]
   PubMedGoogle Scholar
• Sousa D, Pinto D, Araujo R, Rego RO, Moreira-Neto J. Gingival abscess due to an unusual nail-biting habit: a case report. J Contemp Dent Pract 2010; 11(2): 085–91.
   Google Scholar
• de Berker D. Childhood nail diseases. Dermatol Clin 2006; 24(3): 355–63. [CrossRef]
   Web of Science ®Google Scholar
• Ghanizadeh A, Mosallaei S. Psychiatric disorders and behavioral problems in children and adolescents with Tourette syndrome. Brain Dev 2009; 31(1): 15–9. [CrossRef]
   Web of Science ®Google Scholar
• Ghanizadeh A. Association of nail biting and psychiatric disorders in children and their parents in a psychiatrically referred sample of children. Child Adolesc Psychiatry Ment Health 2008; 2(1): 13. [CrossRef]
   Google Scholar
• Ghanizadeh A. Nail biting; etiology, consequences and management. Iran J Med Sci 2011; 36(2): 73–9.
   PubMedGoogle Scholar
• Ghanizadeh A, Bazrafshan A, Firoozabadi A, Dehbozorgi G. Habit Reversal versus Object Manipulation Training for Treating Nail Biting: A Randomized Controlled Clinical Trial. Iran J Psychiatry 2013; 8(2): 61–7.
   PubMedGoogle Scholar
• Berk M, Jeavons S, Dean OM, Dodd S, Moss K, Gama CS, et al. Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting. CNS Spectr 2009; 14(7): 357–60.
   PubMed Web of Science ®Google Scholar
• Leonard HL, Lenane MC, Swedo SE, Rettew DC, Rapoport JL. A double-blind comparison of clomipramine and desipramine treatment of severe onychophagia (nail biting). Arch Gen Psychiatry 1991; 48(9): 821–7. [CrossRef]
   Google Scholar
• Grant JE, Odlaug BL, Chamberlain SR, Keuthen NJ, Lochner C, Stein DJ. Skin picking disorder. Am J Psychiatry 2012; 169(11): 1143–9. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Keuthen NJ, Deckersbach T, Wilhelm S, Hale E, Fraim C, Baer L, et al. Repetitive skin-picking in a student population and comparison with a sample of self-injurious skin-pickers. Psychosomatics 2000; 41(3): 210–15. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Arnold LM, Auchenbach MB, McElroy SL. Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment. CNS Drugs 2001; 15(5): 351–9. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Keuthen NJ, Deckersbach T, Engelhard IM, Forker AE, Baer L, et al. Self-injurious skin picking: clinical characteristics and comorbidity. J Clin Psychiatry 1999; 60(7): 454–9. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Flessner CA, Woods DW. Phenomenological characteristics, social problems, and the economic impact associated with chronic skin picking. Behav Modif 2006; 30(6): 944–63. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Tucker BT, Woods DW, Flessner CA, Franklin SA, Franklin ME. The Skin Picking Impact Project: Phenomenology, interference, and treatment utilization of pathological skin picking in a population-based sample. J Anxiety Disord 2011; 25(1): 88–95. [CrossRef]
   Web of Science ®Google Scholar
• Grant JE, Odlaug BL, Kim SW. Lamotrigine treatment of pathologic skin picking: an open-label study. J Clin Psychiatry 2007; 68(9): 1384–9. [CrossRef]
   Web of Science ®Google Scholar
• Keuthen NJ, Jameson M, Loh R, Deckersbach T, Wilhelm S, Dougherty DD. Open-label escitalopram treatment for pathological skin picking. Int Clin Psychopharmacol 2007; 22(5): 268–74. [CrossRef]
   Web of Science ®Google Scholar
• Hayes SL, Storch EA, Berlanga L. Skin picking behaviors: an examination of the prevalence and severity in a community sample. J Anxiety Disord 2009; 23(3): 314–9. [CrossRef]
   Web of Science ®Google Scholar
• Keuthen NJ, Koran LM, Aboujaoude E, Large MD, Serpe RT. The prevalence of pathologic skin picking in US adults. Compr Psychiatry 2010; 51(2): 183–6. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Teng EJ, Woods DW, Twohig MP. Habit reversal as a treatment for chronic skin picking: a pilot investigation. Behav Modif 2006; 30(4): 411–22. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Schuck K, Keijsers GP, Rinck M. The effects of brief cognitive-behaviour therapy for pathological skin picking: A randomized comparison to wait-list control. Behav Res Ther 2011; 49(1): 11–7. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Simeon D, Stein DJ, Gross S, Islam N, Schmeidler J, Hollander E. A double-blind trial of fluoxetine in pathologic skin picking. J Clin Psychiatry 1997; 58(8): 341–7. [CrossRef]
   PubMed Web of Science ®Google Scholar